Relmada Therapeutics (RLMD) reported a Q1 loss late Tuesday of $0.22 per diluted share, narrowing from a loss of $0.58 a year earlier.

Analysts polled by FactSet expected a loss of $0.20.

The company said it has cash balance of $234 million as of March 31, which is expected to fund operations through 2029, including completion of the NDV-01 phase 3 Rescue program.